ATHERO-FLUX

Targeting novel lipid pathways for treatment of cardiovascular disease

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD    more  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Dr. Nome: Stephen Cognome: Conway Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.atheroflux.eu
Totale costo	7˙861˙350 €
EC contributo	5˙987˙700 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2013-INNOVATION-1
Funding Scheme	CP-FP
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-09-01   -   2018-08-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Dr. Nome: Stephen Cognome: Conway Email: send email Telefono: +44 1865 289800 Fax: +44 1865 289801	UK (OXFORD)	coordinator	1˙036˙150.00
2	ZORA BIOSCIENCES LTD  Organization address address: Biologinkuja 1 city: ESPOO postcode: 2150 contact info Titolo: Ms. Nome: Riikka Cognome: Katainen Email: send email Telefono: 358406000000	FI (ESPOO)	participant	973˙250.00
3	CENIX BIOSCIENCE GMBH  Organization address address: TATZBERG 47 city: DRESDEN postcode: 1307 contact info Titolo: Mrs. Nome: Karen Cognome: Huppertz Email: send email Telefono: +49 3514173161	DE (DRESDEN)	participant	651˙750.00
4	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"  Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Mr. Nome: Dimitris Cognome: Raptis Email: send email Telefono: +30 2106597574	EL (ATHENS)	participant	583˙500.00
5	PIRKANMAA HOSPITAL DISTRICT  Organization address address: TEISKONTIE 35 city: TAMPERE postcode: 33521 contact info Titolo: Mrs. Nome: Leena Cognome: Käppi Email: send email Telefono: 358505000000	FI (TAMPERE)	participant	531˙000.00
6	ROCHE INNOVATION CENTER COPENHAGEN AS  Organization address address: FREMTIDSVEJ 3 city: Horsholm postcode: 2970 contact info Titolo: Dr. Nome: Henrik Cognome: ørum Email: send email Telefono: +45 45179800	DK (Horsholm)	participant	516˙750.00
7	KAROLINSKA INSTITUTET  Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 contact info Titolo: Mrs. Nome: Caroline Cognome: Hamilton Email: send email Telefono: 46851775959 Fax: +468 313147	SE (STOCKHOLM)	participant	456˙000.00
8	INSTITUT PASTEUR  Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 contact info Titolo: Dr. Nome: Marie-Laure Cognome: Rosso Email: send email Telefono: +33 1 44 38 95 26 Fax: +33 1 40 61 39 40	FR (PARIS CEDEX 15)	participant	433˙500.00
9	SYDDANSK UNIVERSITET  Organization address address: CAMPUSVEJ 55 city: ODENSE M postcode: 5230 contact info Titolo: Mrs. Nome: Lone Ladegaard Cognome: Laursen Email: send email Telefono: +45 65502368	DK (ODENSE M)	participant	320˙000.00
10	WEIZMANN INSTITUTE OF SCIENCE  Organization address address: HERZL STREET 234 city: REHOVOT postcode: 7610001 contact info Titolo: Ms. Nome: Talia Cognome: Tzahor Email: send email Telefono: +972 8 934 4026 Fax: +972 8 934 4165	IL (REHOVOT)	participant	315˙800.00
11	ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU  Organization address address: VIA FIORENTINA 151 city: SIENA postcode: 53100 contact info Titolo: Dr. Nome: Cristiana Cognome: Tozzi Email: send email Telefono: +39 0577 587906 Fax: +39 0577 593815	IT (SIENA)	participant	170˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Lipid lowering has significantly reduced cardiovascular disease (CVD) mortality in EU. However, the aim to abolish CVD in EU is far from achieved and attempts to improve on the benefits of statins with new agents have not yet delivered new therapeutics. The Consortium Athero-Flux builds on FP7-generated large-scale lipidomics data showing that specific sphingolipids and in particular distinct ceramides with specific acyl chain lengths are better predictors of CV outcome than traditional risk factors such as low-density lipoprotein-cholesterol. Sphingolipids are implicated in significant biological activities including cell survival, inflammation, and metabolic diseases. Moreover, their levels in metabolic diseases are modulated by previously unrecognized factors such as the gut microflora. Thus, we hypothesize that by controlling sphingolipid metabolism a better primary and secondary prevention of CVD events than with statins alone can be achieved. Athero-Flux builds on cutting-edge SME-led biotechnological tools including: a) high-throughput lipidomic platforms that allow the study of kinetics of lipid metabolism at the molecular lipid level including the new stable isotope labelling technique (Flux); b) whole genome RNA interference screening tools that will allow to identify the regulators of the production of ceramides and the mediators of their biological effect; c) unique locked nucleotide antagonist platforms that have been successfully used clinically in more that 300 patients worldwide. Moreover, it involves Academic partners with top expertise in atherosclerosis, sphingolipid metabolism, and gut microflora to validate targets in the ceramide metabolism. The identification and the validation of the best targets to abate ceramide metabolism though a combination of SME-based leading technology and academia modeling has a strong potential for development of new lipid lowering therapeutics to abate previously unrecognized risk factors for CVD.'